Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals.

Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals.

Item
http://www.wikidata.org/entity/Q42780981
Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical PracticeRaltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovirHIV protease inhibitors disrupt lipid metabolism by activating endoplasmic reticulum stress and inhibiting autophagy activity in adipocytesPopulation pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individualsAcceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infectionUnboosted atazanavir for treatment of HIV infection: rationale and recommendations for use.Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir.Adherence and preexisting major protease inhibitor resistance mutations are associated with virologic failure of a dual-class antiretroviral regimen with inhibitors of HIV-1 viral protease and integrase.
P2860

Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals.

Item
http://www.wikidata.org/entity/Q42780981
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Pharmacokinetics and safety of ...... 400 mg in healthy individuals.
@en
Pharmacokinetics and safety of ...... 400 mg in healthy individuals.
@nl
type
label
Pharmacokinetics and safety of ...... 400 mg in healthy individuals.
@en
Pharmacokinetics and safety of ...... 400 mg in healthy individuals.
@nl
prefLabel
Pharmacokinetics and safety of ...... 400 mg in healthy individuals.
@en
Pharmacokinetics and safety of ...... 400 mg in healthy individuals.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Pharmacokinetics and safety of ...... 400 mg in healthy individuals.
@en
P2093
P304
P31
P356
P433
P478
P50
P577
P698